Palleon Pharma Promotes Li Peng to Chief Scientific Officer

Li Peng is taking on a new role at Palleon Pharmaceuticals as the company’s first chief scientific officer. Peng was previously Palleon’s vice president of research and early product development. Before joining the company, Peng held various roles at AstraZeneca (NYSE: [[ticker:AZN]]). Palleon is developing drugs that target the Siglec-Sialoglycan axis, a mechanism of immune suppression, as an approach to treating cancer and other diseases characterized by immune system dysfunction. In 2017, the Waltham, MA-based biotech closed a $47.6 million Series A round of financing.

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times. View all posts by Frank Vinluan